...
首页> 外文期刊>Biopreservation and biobanking >Method Validation for Preparing Serum and Plasma Samples from Human Blood for Downstream Proteomic, Metabolomic, and Circulating Nucleic Acid-Based Applications
【24h】

Method Validation for Preparing Serum and Plasma Samples from Human Blood for Downstream Proteomic, Metabolomic, and Circulating Nucleic Acid-Based Applications

机译:从人血制备血清和血浆样品用于下游蛋白质组学,代谢组学和循环核酸的方法验证

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Formal method validation for biospecimen processing in the context of accreditation in laboratories and biobanks is lacking. Serum and plasma processing protocols were validated for fitness-for-purpose in terms of key downstream endpoints, and this article demonstrates methodology for biospecimen processing method validation. Methods: Serum and plasma preparation from human blood was optimized for centrifugation conditions with respect to microparticle counts. Optimal protocols were validated for methodology and reproducibility in terms of acceptance criteria based on microparticle counts, DNA and hemoglobin concentration, and metabolomic and proteomic profiles. These parameters were also used to evaluate robustness for centrifugation temperature (4 ?C versus room temperature [RT]), deceleration (low, medium, high) and blood stability (after a 2-hour delay). Results: Optimal protocols were 10-min centrifugation for serum and 20-min for plasma at 2000 g, medium brake, RT. Methodology and reproducibility acceptance criteria were met for both protocols except for reproducibility of plasma metabolomics. Overall, neither protocol was robust for centrifugation at 4 ?C versus RT. RT gave higher microparticles and free DNA yields in serum, and fewer microparticles with less hemolysis in plasma. Overall, both protocols were robust for fast, medium, and low deceleration, with a medium brake considered optimal. Pre-centrifugation stability after a 2-hour delay was seen at both temperatures for hemoglobin concentration and proteomics, but not for microparticle counts. Conclusions: We validated serum and plasma collection methods suitable for downstream protein, metabolite, or free nucleic acid-based applications. Temperature and pre-centrifugation delay can influence analytic results, and laboratories and biobanks should systematically record these conditions in the scope of accreditation.
机译:背景:在实验室和生物库的认证范围内,缺乏对生物样本处理的正式方法验证。血清和血浆处理协议已针对关键下游端点进行了适用性验证,并且本文演示了生物样本处理方法验证的方法。方法:针对微粒数量的离心条件,优化了人血的血清和血浆制剂。根据微粒计数,DNA和血红蛋白浓度以及代谢组学和蛋白质组学特征,根据接受标准对方法和可重复性的最佳方案进行了验证。这些参数还用于评估离心温度(4°C对室温[RT]),减速度(低,中,高)和血液稳定性(延迟2小时后)的鲁棒性。结果:最佳方案是在2000 g,中等制动,RT下对血清离心10分钟,对血浆离心20分钟。除血浆代谢组学的可重复性外,两种方案均符合方法学和可重复性接受标准。总体而言,两种方法都不适合在4°C与RT下进行离心。 RT在血清中产生较高的微粒和游离DNA产量,而在血浆中产生较少溶血的微粒较少。总体而言,这两种方案对于快速,中速和低速减速都具有鲁棒性,其中中速制动被认为是最佳的。血红蛋白浓度和蛋白质组学在两个温度下均能观察到延迟2小时后的离心前稳定性,但对于微粒计数却没有。结论:我们验证了适用于下游蛋白质,代谢产物或基于游离核酸​​的应用的血清和血浆收集方法。温度和离心前延迟会影响分析结果,实验室和生物库应在认证范围内系统记录这些条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号